

ASX Release

TALI TRAIN RECEIVES CE MARK

Melbourne, Australia, 30th August 2019 - Novita Healthcare Limited (ASX: NHL) (“**Novita**” or the “**Company**”) today announced that its breakthrough ATTENTION training technology, **Tali Train** (www.talihealth.com), has received CE Mark certification as a Class I Medical Device. Tali Train is the world’s first software designed to improve attention as a cognitive skill in early childhood. CE Mark certification indicates that Tali Train meets the essential requirements of all the applicable European regulations as a medical device and allows for the sale of Tali Train in the European Economic Area.

Attention related issues such as ADHD affect 5% of school aged children across Europe¹, with inattention the number one globally reported childhood issue. Clinical consensus is that early intervention for attention related issues can potentially avoid billions of dollars in social and economic impacts of the neurodevelopmental disorders such as ADHD². However, current intervention practice in early childhood involves a complex, subjective process, combining clinical judgement with the addition of psychostimulants when appropriate.

Tali Train is a mobile software application used by clinicians, educators and parents to target the strengthening of core attention in children between the development ages of 3 to 8. The program is scientifically and clinically proven to improve attention as a cognitive skill by targeting the core underlying issue which sets it apart from all other brain training or memory-based software applications.

It may also be used as an alternative to psychostimulants and other behavioural training or as a complimentary program making it an ideal “tool in the toolkit” for any clinician or educator globally. The patented software is accessed via an app via an off-the-shelf tablet or iPad and does not require any additional hardware or accessories making it ideal for in-clinic, in-classroom or at home use.

The CE Mark approval was supported by data collected in multiple randomised control clinical trials undertaken by Monash University. CE Mark certification compliments regulatory clearances already achieved for Tali Train in Australia (Class I medical device) and the USA (Class II medical device).

Sue MacLeman Comment

“The achievement of CE Mark for Tali Train further reinforces the global applicability of the Tali platform technology. Clinicians, educators and parents in Europe will now have access to a non-invasive, evidence-based treatment for the most commonly reported issue for children, inattention. Acceleration of the marketing and sales strategy for Europe and the UK as indicated in an ASX release on 30th July 2019, will now commence.”

¹ ADHD Europe: <https://www.adhdeurope.eu/>

² Deloitte Access Economics, 2019: <https://aadpa.com.au/wp-content/uploads/2019/07/Economic-Cost-of-ADHD-To-Australia.pdf>

ABOUT NOVITA

Novita Healthcare Limited (ASX: NHL) is a leading early childhood technology business targeting ATTENTION in children through its breakthrough Tali platform. Tali combines evidence based proprietary algorithms inside a game-based program to assess and strengthen core attention in early childhood (www.talihealth.com).

CONTACT

Glenn Smith

Managing Director

Novita Healthcare Ltd

p: 1300 082 013

e: gsmith@novitahealthcare.com.au

Sue MacLeman

Chair

Novita Healthcare Ltd

p: 1300 082 013

e: smacleman@novitahealthcare.com.au